IL6 and neoplasm: MyD88 mediates the production of inflammatory cytokines such as IL-23 and IL-6, inducing differentiation of Th17 immune cells, upregulating IL-17 and IL-22, and ultimately promoting tumor cell proliferation by activating signaling pathways, including NF-κB and STAT3 (80–82).